UK markets open in 6 hours 44 minutes
  • NIKKEI 225

    27,833.29
    0.00 (0.00%)
     
  • HANG SENG

    26,192.32
    -1,129.66 (-4.13%)
     
  • CRUDE OIL

    72.08
    +0.17 (+0.24%)
     
  • GOLD FUTURES

    1,796.80
    -2.40 (-0.13%)
     
  • DOW

    35,144.31
    +82.76 (+0.24%)
     
  • BTC-GBP

    26,790.20
    +811.42 (+3.12%)
     
  • CMC Crypto 200

    878.97
    -36.52 (-3.99%)
     
  • ^IXIC

    14,840.71
    +3.72 (+0.03%)
     
  • ^FTAS

    4,025.99
    +0.87 (+0.02%)
     

Transparency Notification

·4-min read

THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.

PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION

(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS)

Acacia Pharma Group plc

1. Summary of the notification

Cambridge, UK and Indianapolis, US – 01 July 2021, 08:00 CEST: Acacia Pharma Group plc has received a transparency notification dated 30 June 2021 indicating that Coltrane Asset Management L.P. now holds, by virtue of the sale of shares on 25 June 2021, 4.86% of the voting rights of the company. Coltrane has therefore crossed the threshold of 5%.

2. Content of notification


The notification dated 30 June 2021 contains the following information:

  • Reason of the notification – acquisition or disposal of voting securities or tights

  • Notification by – a parent undertaking or a controlling person

  • Persons subject to the notification requirement:

Name

Address (for legal entities)

Mandeep Manku

250 W 55th St 16C
New York, NY 10019

Coltrane Asset Management Holdings Ltd

94 Solaris Avenue
Camana Bay, Grand Cayman KY1-1108, Cayman Islands

Coltrane Asset Management L.P.

94 Solaris Avenue
Camana Bay, Grand Cayman KY1-1108, Cayman Islands

  • Date on which the threshold is crossed 25 June 2021

  • Threshold that is crossed – 5%

  • Denominator 93,713,951

  • Notified details:

A) Voting rights

Previous notification

After the transaction

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

Linked to securities

Not linked to securities

Linked to securities

Not linked to securities

Mandeep Manku

0

0

0.00%

0.00%

Coltrane Asset Management L.P.

4,931,684

4,844,404

0

4.86%

0.00%

Subtotal

4,844,404

4.86%

TOTAL

4,844,404

0

4.86%

0.00%


B) Equivalent financial instruments

After the transaction

Holders of equivalent financial instruments

Type of financial instrument

Expiration date

Exercise period or date

# of voting rights that may be acquired if the instrument is exercised

% of voting rights

Settlement

TOTAL

0

0.00%

TOTAL (A+B)

# of voting rights

% of voting rights

CALCULATE

4,844,404

4.86%

Full chain of controlled undertakings through which the holding is effectively held:

  • Coltrane Asset Management, L.P. is an investment advisor which manages funds and accounts which hold the shares reported in this filing.

  • Coltrane Asset Management, L.P. can exercise the voting rights at its discretion, without any instruction from its clients.

  • Coltrane Asset Management, L.P. is controlled by Coltrane Asset Management Holdings, Ltd, which is controlled by Mandeep Manku.

3. Miscellaneous

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
MEDiSTRAVA Consulting
+44 20 7638 9571
acaciapharma@medistrava.com

US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

www.acaciapharma.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting